In the news

News can be found on the UCLA Center for Inflammatory Bowel Diseases website

Commentary

Some differences between ACG, ISSA/SHEA C. difficile recommendations (August 27, 2021)
Clinicians have two updated sets of recommendations for managing patients with Clostridioides difficile infection (CDI), and there are some notable differences to consider. Berkeley Limketkai, MD, PhD, director of clinical research, Center for Inflammatory Bowel Diseases, provides commentary on treatment with fidaxomicin and prevention with bezlotoxumab, FMT.

Recent publications

  1. Limketkai BN, Godoy-Brewer G, Parian AM, Noorian S, Krishna M, Shah ND, White J, Mullin GE. Dietary interventions for the treatment of inflammatory bowel diseases: An updated systematic review and meta-analysis. Clinical Gastroenterology and Hepatology. December 5, 2022. doi.org/10.1016/j.cgh.2022.11.026
  2. Limketkai BN, Hamideh M, Shah R, Sauk JS, Jaffe N. Dietary patterns and their association with symptoms of inflammatory bowel diseases. Inflamm Bowel Dis. 2022 Jan 29;izab335.doi: 10.1093/ibd/izab335
  3. Saiki JP, Andreasson JO, Grimes KV, Frumkin LR, Sanjines E, Davidson MG, Park KT, Limketkai B. Treatment-refractory ulcerative colitis responsive to indigo naturalis. BMJ Open Gastroenterol. 2021 Dec;8(1):e000813.doi: 10.1136/bmjgast-2021-000813
  4. Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy. J Gastrointest Surg 2021;25(1):211-9
  5. Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The impact of NAFLD on hospitalization outcomes in patients with inflammatory bowel diseases: nationwide analysis. Inflamm Bowel Dis 2021
  6. Saiki JP, Andreasson JO, Grimes KV, Frumkin LR, Sanjines E, Davidson MG, Park KT, Limketkai B. Treatment-refractory ulcerative colitis responsive to indigo naturalis. BMJ Open Gastroenterol 2021;8(1):e000813
  7. Yelencich E, Truong E, Widaman AM, Pignotti G, Yang L, Jeon Y, Weber AT, Shah R, Smith J, Sauk JS, Limketkai BN. Avoidant restrictive food intake disorder prevalent among patients with inflammatory bowel disease. Clin Gastoenterol Hepatol. 2021 Aug 11;S1542-3565(21)00864-8.
  8. Tripathi K, Godoy Brewer G, Nguyen MT, Singh Y, Ismail MS, Sauk JS, Parian JS, Limketkai BN. COVID-19 and outcomes in patients with inflammatory bowel disease: Sytstemic review and meta-analysis. Inflamm Bowel Dis. 2021 Oct 27; izab236
  9. Dasharathy SS, Limketkai BN, Sauk JS. What's new in the postoperative management of Crohn's disease? Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-021-07205-w
  10. Limketkai BN, Mauldin K, Manitius N, Jalilian L, Salonen BR. The age of artificial intelligence: Use of digital technology in clinical nutrition. Nutrition, Metabolism, and Surgery / Current Surgery Reports. 2021 Article number: 20
  11. Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG clinical guidelines: Prevention, diagnosis and treatment of Clostridioides difficile infections. American Journal of Gastroenterology. June 2021 - Volume 116 - Issue 6 - p 1124-1147 doi: 10.14309/ajg.0000000000001278
  12. Parian AM, Limketkai BN, Chowdhury R, Godoy Brewer G, Salem G, Falloon K, Selaru F, Melia J, Lazarev MG. Serrated epithelial change is associated with high rates of neoplasia in ulcerative colitis patients: A case-controlled study and systemic review with meta-analysis. Inflamm Bowel Dis 2020 Dec 9;izaa312. doi: 10.1093/ibd/izaa312
  13. Palmer LB, Limketkai BN. Modern challenges to gastrointestinal physicians and the nutrition support team: Cautionary tales and call to action. Nutr Clin Pract. 2020 Oct;35(5):855-859. doi: 10.1002/ncp.10552. Epub 2020 Aug 12
  14. Limketkai BN, Singla MB, Rodriguez B, Veerppan GR, Betteridge JD, Ramos MA, Hutfless SM, Brant SR. Levels of vitamin D are low after Crohn's disease is established but not before. Clin Gastroenterol Hepatol. 2020 Jul;18(8):1769-1776.e1
  15. Limketkai BN, Akobeng AK, Gordon M, Adepouju AA. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2020 Jul 17;7(7):CD006634. doi: 10.1002/14651858.CD006634.pub3
  16. Myint A, Sauk JS, Limketkai BN. The role of vitamin D in inflammatory bowel disease: A guide for clinical practice. Expert Rev Gastroenterol Hepatol. 2020 Jul;14(7):539-552. doi: 10.1080/17474124.2020.1775580. Epub 2020 Jun 16
  17. Zikos TA, Hendler S, Clarke JO, Triadafilopoulos G, Nguyen L, Limketkai BN. Reduction in hospitalizations for esophageal reflux in a decade with minimal increases in other functional and motor disorders. Dig Dis Sci. 2020 Jun;65(6):1661-1668. doi: 10.1007/s10620-019-05895-x. Epub 2019 Oct 16
  18. Jeon Y, Limketkai BN. Implications of dietary impact on hepatic steatosis and IBD. Inflamm Bowel Dis. 2020 May 22;izaa098. doi: 10.1093/ibd/izaa098. Online ahead of print
  19. Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping mesalamine therapy in patients with Crohn's disease starting biologic therapy does not increase risk of adverse outcomes. Clin Gastroenterol Hepatol. 2020 May;18(5):1152-1160.e1. doi: 10.1016/j.cgh.2019.08.012. Epub 2019 Aug 13
  20. Chande N, Costello SP, Limketkai BN, Parker CE, Nguyen TM, Macdonald JK, Feagan BG. Alternative and complementary approaches for the treatment of inflammatory bowel disease: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2020 May 12;26(6):843-851.doi: 10.1093/ibd/izz223
  21. Hendler SA, Barber GE, Okafor PN, Chang MS, Limsui D, Limketkai BN. Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwide. Int J Colorectal Dis. 2020 May;35(5):897-903.
    doi: 10.1007/s00384-020-03536-8. Epub 2020 Mar 2
  22. Lechner S, Yee M, Limketkai BN, Pham EA. Fecal microbiota transplantaton for chronic liver diseases: Current understanding and future direction. Dig Dis Sci. 2020 Mar;65(3):897-905.doi: 10.1007/s10620-020-06100-0
  23. Limketkai BN. Biological therapy and recurrent cancer: A threat no more? Lancet Gastroenterol Hepatol. 2020 Mar;5(3):233-234.doi: 10.1016/S2468-1253(19)30403-0. Epub 2019 Dec 10
  24. Limketkai BN, Gordon M, Mutlu EA, De Silva PS, Lewis JD. Diet therapy for inflammatory bowel diseases: A call to the dining table. Inflamm Bowel Dis. 2020 Mar 4;26(4):510-514.doi: 10.1093/ibd/izz297
  25. Yu JX, Lin JL, Oliver M, Soetikno R, Chang MS, Kwong AJ, Limketkai BN, Bhattacharta J, Kaltenbach T. Trends in EMR for nonmalignant colorectal polyps in the Unitesd States. Gastrointest Endosc. 2020 Jan;91(1):124-131.e4. doi: 10.1016/j.gie.2019.08.004. Epub 2019 Aug 19
  26. Limketkai BN, Shah SC, Hirano I, Bellaguarda E, Colombel JF. Epidemiology and implications of concurrent diagnosis of esoinophilic oesophagitis and IBD based on a prospective population-based analysis. Gut. 2019 Dec;68(12):2152-2160. doi: 10.1136/gutjnl-2018-318074. Epub 2019 Mar 28
  27. Weber AT, Shah Neha D, Sauk J, Limketkai BN. Popular diet trends for inflammatory bowel diseases: Claims and evidence. Curr Treat Options Gastroenterol. 2019 Dec;17(4):564-576. doi: 10.1007/s11938-019-00248-z
  28. Tran V, Limketkai BN, Sauk JS. IBD in the elderly: Management challenges and therapeutic considerations. Curr Gastroenterol Rep. 2019 Nov 27;21(11):60. doi: 10.1007/s11894-019-0720-7
  29. Keyashian K, Dehghan M, Sceats L, Kin C, Limketkai BN, Park KT. Comparative incidence of inflammatory bowel diseas in different age groups in the United States. Inflamm Bowel Dis. 2019 Nov 14;25(12):1983-1989. doi: 10.1093/ibd/izz092
  30. Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. US practice patterns and impact of monitoring for mucosal inflammation after biologic initiation in inflammatory bowel disease. Inflamm Bowel Dis. 2019 Oct 18;25(11):1828-1837. doi: 10.1093/ibd/izz081
  31. Yu JX, Oliver M, Lin J, Chang M, Limketkai BN, Soetikno R, Bhattacharya J, Kaltenbach T. Patients prescribed direct-acting oral anticoalgulants have low risk of postpolypectomy complications. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2000-2007.e3.doi: 10.1016/j.cgh.2018.11.051. Epub 2018 Nov 29
  32. Limketkai BN, Shah ND, Sheikh GN, Allen K. Classifying enteral nutrition: Tailored for clinical practice. Curr Gastroenterol Rep. 2019 Jul 31;21(9):47. doi: 10.1007/s11894-019-0708-3
  33. Unargo RC, Limketkai BN, Bjørn Jensen C, Højgaard Allin K, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: Analysis of two nationwide population-based cohorts. Gut. 2019 Jun;68(6):977-984. doi: 10.1136/gutjnl-2018-317021. Epub 2018 Nov 12
  34. Limketkai BN. IBD hospitalisation trends provide insight for future study. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):259-260. doi: 10.1016/S2468-1253(19)30037-8. Epub 2019 Feb 12
  35. Limketkai BN, Iheozor-Ejiofor Z, Gjuladin-Hellon T, Parian A. Matarese LE, Bracewell K, MacDonald JK, Gordon M, Mullin GE. Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2019 Feb 8;2(2):CD012839. doi: 10.1002/14651858.CD012839.pub2
  36. Limketkai BN, Hendler S, Ting PS, Parian AM. Fecal microbial transplantation for the critically ill patient. Nutr Clin Pract. 2019 Feb;34(1):73-79. doi: 10.1002/ncp.10228. Epub 2018 Dec 18
  37. Choe MY, Shah ND, Regalia, Limketkai BN. Intestinal dysmotility mimicking obstruction in patients withprior bowel resection study. Gastroenterol Nurs. Jan/Feb 2019;42(1):95-100.doi: 10.1097/SGA.0000000000000425
  38. Wong JJ, Sceats L, Dehghan M, Wren AA, Sellers ZM, Limketkai BN, Bensen R, Kin, C, Park KT. Depression and health care use in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Jan 1;13(1):19-26. doi: 10.1093/ecco-jcc/jjy145